Research Centre of Personalized Oncology
Research Centre of Personalized Oncology
Head of the Centre — Konstantin Samochernykh.
Major tasks
The scientific significance of fundamental developments in the field of oncology as part of the work of the WCRC for Personalized Medicine is determined by the use of the latest gene expression analysis technologies, including single cell sequencing, genomic analysis combined with epigenetic profiling and high-throughput sequencing.
Data on the genomic structure of solid and hematopoietic tumors obtained using the material of existing and future bioresource collections, combined with the possibility of detailed patient phenotyping at medical centers of the Consortium will allow developing new criteria that determine the chemo- and radiosensitivity of tumors, creating genetic diagnostic systems and new genetically engineered drugs for cancer treatment, determining new genetic markers for personalized targeted therapy for a number of tumors.
Important areas of the Oncology program are the study of the fundamental mechanisms of drugs utilizing chimeric antigen receptors, the use of genetically modified immune cells and the search for methods to create biomedical cell products of this kind.
Focus areas
- Molecular and genetic profiling of CNS tumors for personalized combined therapy.
- Searching for new molecular and genetic markers for the prediction of the clinical course of neuroendocrine tumors.
- Molecular profiling of pancreatic and pancreato-biliary tumors and borderline neoplasms to determine personalized surgical and chemotherapy tactics.
- Chimeric antigen receptor T cells (CAR-T) for colorectal cancer therapy using a new method of bispecific receptors.
- Chimeric antigen receptor T cells (CAR-T) for the treatment of multiple myeloma using a new type of costimulatory domains.
- Immunological markers as predictors of response to tyrosine kinase inhibitors and targets for therapy for myeloproliferative disorders.
- Single cell sequencing as a method for determining tumor heterogeneity and therapy strategy.
- Studying the immune landscape of acute leukemia to create a patient's individual immune profile in order to personalize therapy based on this profile.
- Developing methods to increase the efficacy and safety of haploidentical bone marrow transplantation based on the studied characteristics of immune recovery and cell-mediated adaptive immune technologies.
- Developing of RAS70 peptide agent against membrane-bound HSP70 on cancer cells for targeted intraoperative imaging of malignant tumors.
- Developing and obtaining oncolytic bacterial and viral strains for the treatment of intestinal, pancreato-biliary and brain tumors.
- Creating a line of radiopharmaceuticals for determining the radiation phenotype of malignant tumors of various sites in order to personalize antitumor treatment.
- Developing an approach to improve the long-term outcomes of treatment for cancer patients by using personalized microbial therapy.
- Studying the role of microbiota in the development and progression of female genital tumors.
- Developing a neural network algorithm for early diagnosis of tumors of the female reproductive system (cervical cancer) based on colposcopic screening.
- Creating programmes for the analysis of endoscopic ultrasound videos and images based on artificial intelligence for higher diagnostic accuracy.
- Developing personalized minimally invasive and palliative endoscopic techniques for the treatment of pancreatobiliary tumors and endoscopic administration of chemotherapy drugs.
- Personalizing the management of cancer patients in order to preserve fertility.
- Developing a personalized decision support system for choosing the tactics in patients with malignant tumors of various sites and severe cardiovascular comorbidities.
Structure
Major publications
- Genetic polymorphisms associated with rheumatoid arthritis development and antirheumatic therapy response. Mikhaylenko D. S., Nemtsova M. V., Bure I. V., Deviatkin A.A., Zamyatnin A.A. International Journal of Molecular Sciences, 2020, 21(14), р. 1-17.
- Antihypertensive effect of amlodipine in co-administration with omeprazole in patients with hypertension and acid-related disorders: Cytochrome P450-associated aspects. Dorofeeva M. N., Shikh E. V., Sizova Z. M., Grishina E. A., Sychev D. A. Pharmacogenomics and Personalized Medicine, 2019, 12, р. 329-339
- Roles of e-cadherin and noncoding rnas in the epithelial–mesenchymal transition and progression in gastric cancer. Bure I. V., Nemtsova M. V., Zaletaev D. V. International Journal of Molecular Sciences, 2019, 20(12), 2870 Q1
- Epigenetic changes in the pathogenesis of rheumatoid arthritis. Nemtsova M. V., Zaletaev D. V., Bure I.V., Lukashev A. N., Zamyatnin A. A. Frontiers in Genetics, 2019, 10(JUN), 570 Q1
- Antihypertensive effect of amlodipine in co-administration with omeprazole in patients with hypertension and acid-related disorders: Cytochrome P450-associated aspects. Dorofeeva M. N., Shikh E. V., Sizova Z. M., Grishina E. A., Sychev D. A. Pharmacogenomics and Personalized Medicine, 2019, 12, р. 329-339
- Long noncoding RNA HOTAIR is upregulated in an aggressive subgroup of gastrointestinal stromal tumors (GIST) and mediates the establishment of gene-specific DNA methylation patterns. Bure I., Geer S., Knopf J., Haller F., Moskalev E.A. Genes Chromosomes and Cancer, 2018, 57(11), с. 584-597
- Neumann H. P. H., Tsoy U., Bancos I., Amodru V., Walz M. K., Tirosh A., et al; International Bilateral-Pheochromocytoma-Registry Group (Grineva E.N. among the International Bilateral-Pheochromocytoma-Registry Group). Comparison of Pheochromocytoma-Specific Morbidity and Mortality among Adults with Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.//JAMA Network Open. - 2019. Aug 2;2(8):e198898. DOI: 10.1001/jamanetworkopen.2019.8898
- Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Casanueva F. F., Barkan A. L., Buchfelder M., Klibanski A., Laws E. R., Loeffler J. S., Melmed S., Mortini P., Wass J., Giustina A.; Pituitary Society, Expert Group on Pituitary Tumors.Pituitary. 2017 Oct;20(5):489-498. doi: 10.1007/s11102-017-0838-2.
- Shuvalov O., Kizenko A., Petukhov A., Aksenov N., Fedorova O., Vorobev M., Daks A., Barlev N. Cancer-testis antigens, semenogelins 1 and 2, exhibit different anti-proliferative effects on human lungadenocarcinoma cells. Cell Death Discov. 2020;6:108. doi: 10.1038/s41420-020-00336-5. eCollection 2020. PubMed PMID: 33101710; PubMed Central PMCID: PMC7581521.
- Fedorova O., Daks A., Shuvalov O., Kizenko A., Petukhov A., Gnennaya Y., Barlev N. Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. Cell Death Discov. 2020;6:100. doi: 10.1038/s41420-020-00337-4. eCollection 2020. Review. PubMed PMID: 33083021; PubMed Central PMCID: PMC7548004.
- Vasileva E., Shuvalov O., Petukhov A., Fedorova O., Daks A., Nader R., Barlev N. KMT Set7/9 is a new regulator of Sam68 STAR-protein. Biochem Biophys Res Commun. 2020 May 14;525(4):1018-1024. doi: 10.1016/j.bbrc.2020.03.017. Epub 2020 Mar 13. PubMed PMID: 32178870.
- Titov A., Valiullina A., Zmievskaya E., Zaikova E., Petukhov A., Miftakhova R., Bulatov E., Rizvanov A. Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers (Basel). 2020 Jan 3;12(1). doi: 10.3390/cancers12010125. Review. PubMed PMID: 31947775; PubMed Central PMCID: PMC7016531.
- Efimova O. A., Koltsova A. S., Krapivin M. I., Tikhonov A. V., Pendina A. A. Environmental Epigenetics and Genome Flexibility: Focus on 5-Hydroxymethylcytosine. International Journal of Molecular Sciences. 2020;21(9):3223.
- Sharma N., Fonin A. V., Shpironok O. G., Silonov S. A., Turoverov K. K., Uversky V. N. Folding perspectives of an intrinsically disordered transactivation domain and its single mutation breaking the folding propensity. Int. J. Biomacromol, 2019.
-
Shevtsov M., Stangl S., Nikolaev B., Yakovleva L., Marchenko Y., Tagaeva R., Sievert W., Pitkin E., Mazur A., Toltoy P., Galibin O., Ryzhov V., Steiger K., Smirnov O., Khachatryan W., Chester K., Multhoff G. Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. Small. 2019; 15(13):e1900205. WoS IF = 10.856, Q1
-
Goryaynov S. A., Okhlopkov V. A., Golbin D. A., Chernyshov K. A., Svistov D. V., Martynov B. V., Kim A. V., Byvaltsev V. A., Pavlova G. V., Batalov A., Konovalov N. A., Zelenkov P. V., Loschenov V. B., Potapov A. A. Fluorescence Diagnosis in Neurooncology: Retrospective Analysis of 653 Cases. Front Oncol. 2019;9:830. WoS IF = 4.848, Q1
- Shevtsov M., Sato H., Multhoff G., Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Frontiers in Oncology. 2019;9:156. WoS IF = 4.25, Q1
- Shevtsov M., Pitkin E., Ischenko A., Stangl S., Khachatryan W., Galibin O., Edmond S., Lobinger D., Multhoff G. Ex vivo Hsp70-activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Frontiers in Immunology. 2019;10:454. WoS IF = 4.716, Q1
- Stangl S., Tei L., De-Rose F., Reder S., Martinelli J., Sievert W., Shevtsov M., Öllinger R., Rad R., Schwaiger M., Alessandria C.D., Multhoff G. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Cancer Research. 2018;78(21):6268-628. WoS IF = 8.378, Q1
- Shevtsov M., Nikolaev B., Marchenko Y., Yakovleva L., Skvorzov N., Mazur A., Tolstoy P., Ryzhov V., Multhoff G. Targeting experimental glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs). International Journal of Nanomedicine. 2018;13:1471-1482. WoS IF = 4.471, Q1
- Stangl S., Tontcheva N., Sievert W., Shevtsov M., Niu M., Schmid T. E., Pigorsch S., Combs S. E., Haller B., Balermpas P., Rödel F., Rödel C., Fokas E., Krause M., Linge A., Lohhaus F., Baumann M., Tinhofer I., Budach V., Stuschke M., Grosu A.L., Abdollahi A., Debus J., Belka C., Maihöfer C., Mönnich D., Zips D., Multhoff G. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer. 2018;142(9):1911-1925. WoS IF = 4.982, Q1
- Shevtsov M. A., Parr M. A., Ryzhov V. A., Zemtsova E. G., Ponomareva A. N., Smirnov V. M., Multhoff G. Zero-valent Fe confined mesoporous silica nanoparticles (Fe(0)@MCM-41) for targeting experimental orthotopic glioma in rats. Scientific Reports. 2016;6:29247. WoS IF = 4.011, Q1
-
Marina V. Filimonova, Victoria M. Makarchuk, Ljudmila I. Shevchenko, Alina S. Saburova, Valentina I. Surinova, Olga S. Izmestieva, Anatoly A. Lychagin, Vyacheslav O. Saburov, Petr V. Shegay, Andrey D. Kaprin, Sergey A. Ivanov, Alexander S. Filimonov / Radioprotective Activity of the Nitric Oxide Synthases Inhibitor T1023. Toxicological and Biochemical Properties, Cardiovascular and Radioprotective Effects // Radiation Research, 2020, принята к публикации 3.08.20.
-
Saburova A. S., Filimonova M. V., Yuzhakov V. V., Shevchenko L. I., Yakovleva N. D., Bandurko L. N., Koretskaya A. E., Fomina N. K., Saburov V. O., Filimonov A. S. / The influence of nitric oxide synthases inhibitor Т1023 on the development of radiation pneumofibrosis in rats // Radiatsionnaya Gygiena, 2020, 13(1), р. 60-67 DOI: 10.21514/1998-426Х-2020-13-1-60-67
- Alexeev A. A., Nurieva E. V., Trofimova T. P., Chesnakova E. A., Grishin Y. K., Lyssenko K. A., Filimonova M. V., Zefirova O. N. / Bicyclic bridged isothioureas: synthesis and evaluation of activity in a model of lipopolysaccharide-induced septic shock // Mendeleev Communications, 2019, 29(1), p. 14-16 DOI: 10.1016/j.mencom.2019.01.003
- Nurieva E. V., Trofimova T. P., Alexeev A. A., Proshin A. N., Chesnakova E. A. d., Grishin Y. K., Lyssenko K. A., Filimonova M. V., Bachurin S. O., Zefirova O. N. / Synthesis and antihypotensive properties of 2-amino-2-thiazoline analogues with enhanced lipophilicity // Mendeleev Communications, 2018, 28(4), с. 390-392 DOI: 10.1016/j.mencom.2018.07.016
- Filimonova M. V., Podosinnikova T. S., Samsonova A. S., Makarchuk V. M., Shevchenko L. I., Filimonov A. S. / Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate // Bulletin of Experimental Biology and Medicine, 2019, 168(1), p. 92-94 DOI: 10.1007/s10517-019-04655-1
- Efimenko I. A., Filimonova M. V., Churakov A. V., Ivanova N. A., Erofeeva O. S., Samsonova A. S., Podosinnikova T. S., Filimonov A. S. / First Polynuclear Palladium Compounds [(C5H12NO)(PdCl3)]n and [(C10H16NO)2(Pd2Cl6)] with High Antitumor and Radioprotective Activity // Russian Journal of Coordination Chemistry/Koordinatsionnaya Khimiya, 2020, 46(5), р. 339-349 DOI: 10.1134 / S1070328420040028
- Filimonova M. V., Shevchenko L. I., Makarchuk V. M., Chesnakova E. A., Shevchuk A. S., Filimonov A. S., Kryzhanovskii S. A. / Vasopressor Properties of No Synthase Inhibitor T1059. Part II. Hemodynamic Effects on Hypovolemic Disorders // Pharmaceutical Chemistry Journal, 2020, 53(12), р.1113-1117 DOI: 10.1007/s11094-020-02132-y
- Makarchuk V. M., Filimonova M. V., Filimonov A. S., Shevchenko L. I., Izmestieva O. S., Saburova A. S. / Lactatemia as a possible pharmacological marker of NOS-inhibitor T1023 induced radioresistance / Radiation and Risk, 2020, 29(1), р. 45-56 DOI: 10.21870 / 0131-3878-2020-29-1-45-56
- Filimonova M. V., Evstratova E. S., Makarchuk V. M., Shevchenko L. I., Filimonov A. S., Petin V. G. / Involvement of Recovery Processes in the Effects of Radioprotectors at the Cellular and Organismal Levels // Biology Bulletin, 2019, 46(12),p. 1619-1624 DOI: 10.1134/S1062359019120033
- Filimonova M. V., Shevchenko L. I., Makarchuk V. M., Chesnakova E. A., Surinova V. I., Shevchuk A. S., Filimonov A. S., Kryzhanovskii S. A., Shevchenko T. F., Bugrova A. E., Kalamkarov G. R. / Vasopressor Properties of Nitric Oxide Synthase Inhibitor T1059. Part I: Synthesis, Toxicity, NOS-Inhibition Activity, and Hemodynamic Effects Under Normotensive Conditions // Pharmaceutical Chemistry Journal, 2018, 52(4), с. 294-298 DOI: 10.1007/s11094-018-1809-2
- Filimonova M. V., Samsonova A. S., Korneeva T. S., Shevchenko L. I., Filimonov A. S. / Study of the ability of a new nitric oxide synthase inhibitor INOS1 to selectively protect the normal tissue in the Ehrlich carcinoma radiotherapy model // Radiation and Risk, 2018, 27(2), с. 37-45 DOI: 10.21870 / 0131-3878-2018-27-2-37-45
- Filimonova M. V., Samsonova A. S., Korneeva T. S., Shevchenko L. I., Saburov V. O., Filimonov A. S. / The radioprotective effects of nitric oxide synthase inhibitor T1023 on normal and malignant tissues // Radiation and Risk, 2018, 27(2), с. 37-45 DOI: 10.21870 / 0131-3878-2018-27-4-155-169
- Simakova M. A., Karpova D. V., Marukyan N. V. et. al Dual-energy computed tomography-angiography in the evaluation and management of significant multiple pulmonary vein stenoses following atrial fibrillation ablation Pulmonary Circulation 2020; 10(4) 1–3 DOI: 10.1177/2045894020969499
- Antuganov D., Zykov M., Timofeev V. et al.
- Copper‐mediated radiofluorination of aryl pinacolboronate esters: a straightforward protocol by using pyridinium sulfonates.
European journal of organic chemistry. 2019; 5: 918–922. DOI:10.1002/ejoc.201801514.
- Antuganov D., Timofeev V., Timofeeva K. et al.
Evaluation of protic ionic liquids based on triethanolammonium and Tris (hydroxymethyl) methylammonium salts as buffers for Ga-68-radiolabelling of PSMA-HBED-CC.
Chemistry select. 2019; 4 (43): 12524–12527. DOI: 10.1002/slct.201902588.
- Antuganov D., Antuganova Y., Zykova T. et al.
Use of capillary electrophoresis for the determination of impurities in preparations of fluorine-18 labelled PET radiopharmaceuticals.
Journal of pharmaceutical and biomedical analysis. 2019; 173: 68–74. DOI: 10.1016/j.jpba.2019.05.016.
- Antuganov D., Zykov M., Timofeeva K. et al.
Effect of Pyridine Addition on the Efficiency of Copper-Mediated Radiofluorination of Aryl Pinacol Boronates.
2017; 2 (26): 7909–7912. DOI.10.1002/slct.201701628.
Contacts
Konstantin Samochernykh, Head of the Centre
e-mail: samochernykh_ka@almazovcentre.ru
